In parallel, the PRGN-2009 trial (NCT04432597) is assessing a therapeutic HPV vaccine, alone or in combination with M7824 (a bifunctional fusion protein targeting both PD-L1 and TGF-β), in HPV-positive head and neck cancers. This evidence concerns the gene CD274 and head and neck cancer.